#Bitopertin
LightNews LightNews
hemehub.bsky.social
🩸Facts about Acute Hepatic Porphyria:

Investigational treatments, iron supplementation in EPP1 and XLEPP, and limitations of urine PBG screening.

#EPP #XLEPP #EPP1 #Dersimelagon #Bitopertin #Afamelanotide #MC1R #GlyT1 #ALAS2 #PPIX #Porphyria #Hematology #HemeOnc #MedEd #HemeHub
November 1, 2026 at 5:05 AM
hemehub.bsky.social
🩺💡Today’s questions!

Swipe to see the answers and explanations!

#AHP #AIP #EPP #Givosiran #Dersimelagon #Bitopertin #Afamelanotide #Porphyria #ClinicalTrials #Hematology #MedicalEducation #MedEd #HemeHub
October 30, 2026 at 5:10 PM
hemehub.bsky.social
🎯Today’s questions!

Swipe to see the answers and explanations!

#HemeHub #Hematology #HemeOnc #AHP #AcuteHepaticPorphyria #Porphyria #Givosiran #Hepatocytes #MedEd #EPP #Porphyria #Afamelanotide #Bitopertin #GlyT1
October 26, 2026 at 10:35 PM
rarediseasereadout.bsky.social
Also this week: Disc's bitopertin for the sun-sensitivity disease EPP met every goal in the Phase 3 trial the FDA asked for, Biohaven's rejected ataxia drug troriluzole is getting a second FDA review, and Merck KGaA is buying Silence Therapeutics for about $1.3B. (Not medical advice.)
October 26, 2026 at 6:32 PM
merlintrader.bsky.social
$IRON Latest company news, Oct 22, 2026: Disc Medicine closed its offering of 6M shares at $75: about $422.4M net, up to roughly $485.9M if the underwriters take the full option.

https://www.merlintrader.com/disc-medicine-stock-hub/
Disc Medicine $IRON: Bitopertin And APOLLO
Disc Medicine $IRON research on APOLLO, bitopertin's FDA path, hematology programs, cash, debt, dilution and the evidence needed after the CRL.
www.merlintrader.com
October 23, 2026 at 8:16 AM
merlintrader.bsky.social
$IRON Latest company news, Oct 20, 2026: Disc Medicine priced an upsized public offering of 6,000,000 shares at $75.00, for expected gross proceeds of $450 million; underwriters have a 30-day option on up to 900,000 more shares.

https://www.merlintrader.com/disc-medicine-stock-hub/
Disc Medicine $IRON: Bitopertin And APOLLO
Disc Medicine $IRON research on APOLLO, bitopertin's FDA path, hematology programs, cash, debt, dilution and the evidence needed after the CRL.
www.merlintrader.com
October 21, 2026 at 4:52 PM
market-scanner.bsky.social
$IRON — Disc Medicine's (IRON) stock surged on positive Phase 3 trial results for bitopertin, alongside a proposed securities offering.

Successful Phase 3 APOLLO trial results for bitopertin met all primary and secondary endpoints.

https://market-scanner.net/tickers/IRON.US

#ai #trading
IRON.US — AI analysis summary
Descriptive, non-directional summary of recent AI analyses.
market-scanner.net
October 20, 2026 at 12:33 PM
firstwordgroup.com
Disc's Phase III data breathes new life into FDA-rejected bitopertin #$IRON firstwordpharma.com/story/8239299
October 20, 2026 at 3:42 AM
novelstartup.bsky.social
Stock Market Today: IRON Soars 38.86% on Bitopertin Trial Success

https://novelstartup.com/market-movers/stock-market-today-iron-soars-38-86-on-bitopertin-trial-success/
Stock Market Today: IRON Soars 38.86% on Bitopertin Trial Success | NovelStartUp
Tracking Growth Stocks, Tech Catalysts, and Market-Moving Equities
novelstartup.com
October 19, 2026 at 10:40 PM
merlintrader.bsky.social
$IRON Latest news, October 20, 2026: after the APOLLO Phase 3 readout, Wedbush raised its target on Disc Medicine to $110 from $100, Wells Fargo to $124 from $86 and Truist to $115 from $83, all keeping positive ratings (third-party opinions).

https://www.merlintrader.com/disc-medicine-stock-hub/
Disc Medicine $IRON: Bitopertin And APOLLO
Disc Medicine $IRON research on APOLLO, bitopertin's FDA path, hematology programs, cash, debt, dilution and the evidence needed after the CRL.
www.merlintrader.com
October 20, 2026 at 6:14 PM
merlintrader.bsky.social
Disc Medicine: Phase 3 APOLLO of bitopertin in EPP met both co-primary and all secondary endpoints. $IRON

https://www.merlintrader.com/disc-medicine-stock-hub/
Disc Medicine $IRON: Bitopertin And APOLLO
Disc Medicine $IRON research on APOLLO, bitopertin's FDA path, hematology programs, cash, debt, dilution and the evidence needed after the CRL.
www.merlintrader.com
October 19, 2026 at 5:53 PM
thelunaletter.bsky.social
Disc Medicine (IRON) said bitopertin met all primary and secondary goals in its Phase 3 APOLLO trial in erythropoietic protoporphyria (EPP), a rare disorder that makes sunlight painful, after the FDA turned it down on 13 Feb 2026.
October 20, 2026 at 10:30 AM
merlintrader.bsky.social
#$IRON: Disc Medicine says Phase 3 APOLLO of bitopertin in EPP met all primary and secondary endpoints, with no new safety signals. NDA resubmission planned by end of 2026.

Disc Medicine #$IRON: Bitopertin And APOLLO

www.merlintrader.com/disc-medicin...
October 19, 2026 at 2:07 PM
secwatch.bsky.social
🚨 JUST IN: $IRON
Disc Medicine's bitopertin meets all Phase 3 APOLLO endpoints in EPP; NDA resubmission planned for end-2026

#SEC #stocks #investing #IRON
🔗 secwatch.observer
Disc Medicine's bitopertin meets all Phase 3 APOLLO endpoints in EPP; NDA resubmission planned for end-2026
October 19, 2026 at 11:22 AM
notreload.bsky.social
#$IRON bitopertin succeeded on all primary and secondary endpoints in the APOLLO Phase 3 trial, sending the stock sharply higher. notreload.xyz/xy/iron-soar...
Disc Medicine Soars After Positive Phase 3 EPP Trial Results
Disc Medicine’s bitopertin succeeded on all primary and secondary endpoints in the APOLLO Phase 3 trial, sending the stock sharply higher.
notreload.xyz
October 19, 2026 at 11:50 AM
endpts.com
After an FDA rejection, Disc Medicine’s drug for a rare disease that makes sun exposure painful hit all endpoints in Phase 3.
After FDA rejection, Disc Medicine's 'sun allergy' drug hits home run in Phase 3
Disc Medicine's bitopertin met all Phase 3 APOLLO endpoints for EPP, showing 12.2 more pain-free light hours and 41.4% PPIX reduction vs placebo.
endpoints.news
October 19, 2026 at 1:43 PM
knowfirst.bsky.social
Disc Medicine (IRON) reported that its Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria met all co-primary and secondary endpoints, with shares rising more than…

$IRON $CLVT named in the read, sent 12:57:00 PM ET. One of 32 alerts today.
knowfir.st
October 19, 2026 at 7:12 PM
marketflux.bsky.social
#Healthcare Disc Medicine shares surged as much as 63% on October 19 after the company announced that its investigational drug bitopertin met all primary and secondary endpoints in the pivotal Phase 3 APOLLO trial for erythropoietic protoporphyria, a rare disorder in which sunli ... Continue reading
October 19, 2026 at 3:20 PM
stocktitan.net
#IRON Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial of Bitopertin in Adul…

https://www.stocktitan.net/news/IRON/disc-medicine-announces-success-on-all-primary-and-secondary-lme76zfyu0h1.html?utm_source=stocktitan-bluesky&utm_medium=social
Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial of Bitopertin in Adults and Adolescents with Erythropoietic Protoporphyria (EPP)
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
October 19, 2026 at 11:00 AM
stocktitan.net
#IRON Disc Medicine to Host Corporate Webcast to Discuss Topline Results from the APOLLO Phase 3 Trial of Bitopertin in Erythrop…

https://www.stocktitan.net/news/IRON/disc-medicine-to-host-corporate-webcast-to-discuss-topline-results-m7c7fftkewjx.html?utm_source=stocktitan-bluesky&utm_medium=social
Disc Medicine to Host Corporate Webcast to Discuss Topline Results from the APOLLO Phase 3 Trial of Bitopertin in Erythropoietic Protoporphyria (EPP)
Disc Medicine (IRON) will host a webcast on October 19, 2026, to discuss topline results from its APOLLO Phase 3 trial. The trial evaluates bitopertin in erythropoietic protoporphyria (EPP). The webcast starts at 8:00 a.m. ET, with registration through the Events and Presentations page of Disc’s website. A replay will be available on the website afterward.
www.stocktitan.net
October 18, 2026 at 9:00 PM
thedeskresearch.bsky.social
Deep Dive: Disc Medicine Surges on Phase 3 APOLLO Readout: Can Pivotal Data Overcome Bitopertin’s Earlier Regulatory Rejection? — Disc Medicine, Inc. shares rallied on October 19, 2026, after the clinical-stage biopharm…

I publish The Desk. General research only; not personalized investment advice.
Disc Medicine Surges on Phase 3 APOLLO Readout: Can Pivotal Data Overcome Bitopertin’s Earlier Regulatory Rejection?
Disc Medicine, Inc. shares rallied on October 19, 2026, after the clinical-stage biopharmaceutical company announced positive topline results from its pivotal Phase 3 APOLLO trial evaluating bitopertin in patients with erythropoietic protoporphyria (EPP) and X-linked…
www.thedeskresearch.com
October 20, 2026 at 5:34 AM
quant-hub.bsky.social
🚨 $IRON
On October 19, 2026, Disc Medicine, Inc. issued a press release titled “Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial of Bitopertin in Adults and Adolescents with Erythropoietic Protoporphyria (EPP).” A copy of the press release...
SEC Filing: IRON
Click to view the official SEC document.
www.sec.gov
October 19, 2026 at 11:08 AM
merlintrader.bsky.social
Disc Medicine #$IRON: Bitopertin and APOLLO

APOLLO data are guided for Q4. After the FDA complete response letter, the central question is clinical benefit, not just lower protoporphyrin.

www.merlintrader.com/disc-medicin...
Disc Medicine $IRON: Bitopertin And APOLLO
Disc Medicine $IRON research on APOLLO, bitopertin's FDA path, hematology programs, cash, debt, dilution and the evidence needed after the CRL.
www.merlintrader.com
October 9, 2026 at 11:26 PM
embers.news
Disc Medicine Updates Clinical Programs for DISC-3405 and Bitopertin

Disc Medicine is advancing its two primary clinical candidates, DISC-3405 and bitopertin, as the company adjusts…

Read more: https://embers.news/article/disc-medicine-updates-clinical-programs-for-disc-3405-and-bitopertin-74668
Disc Medicine Updates Clinical Programs for DISC-3405 and Bitopertin
Disc Medicine is advancing its two primary clinical candidates, DISC-3405 and bitopertin, as the company adjusts its regulatory strategy following FDA feedback. The firm is focused on demonstrating clinical efficacy for polycythemia vera while pursuing a traditional approval pathway for its erythrop
embers.news
September 26, 2026 at 2:20 PM
salsbblue.bsky.social
Bitopertin scored 1.382 for DAT and 0.794 for GlyT1 by Exponential Consensus Ranking across three docking programs.
Article: www.tandfonline.com/doi/full/10....
Audio: open.spotify.com/episode/323O...
#JBSD
Black-and-gold JBSD infographic with a labeled ranking schematic. A geometric Bitopertin node branches to DAT, ECR 1.382, in gold and GlyT1, ECR 0.794, in teal. Bitopertin scores higher for DAT than GlyT1. Two smaller annotations identify NFPS_2 as first for GlyT1 at ECR 1.896 and Org 24598_2 as first for GlyT2 at ECR 1.075. ECR combines ranks from AutoDock Vina, GOLD and DockThor. Source: Nascimento and colleagues, Section 3.3 and Figure 4.
September 23, 2026 at 12:56 PM